ClinicalTrials.gg
CompletedNCT05513742COMPANION-003Updated Sep 25, 2026Results posted

A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer

A Phase 2 interventional study of CTX-009 in Metastatic Colorectal Cancer, Colon Cancer and Rectal Cancer, sponsored by Compass Therapeutics. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Compass Therapeutics · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,112th of 1,934
49 · median 64
Started
2022
with 126 others
Phase 2
511 of 2,342
66 open now
Registered
1,794th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 1,112th largest by enrollment of the 1,934 interventional ones that give a count, is one of 127 that started in 2022, is one of 511 in phase 2, and was the 1,794th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.

A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

03

Conditions studied

  • Metastatic Colorectal Cancer
  • Colon Cancer
  • Rectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. or cytologically confirmed or recurrent colorectal cancers
  3. The primary tumor must have been resected > 3 months prior to planned C1D1.
  4. Patients who experienced progressive disease or relapse after receiving two or three in the locally advanced or metastatic setting. Prior lines of systemic treatment must have included at least one fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab containing chemotherapy regimen (in any combination and may have been administered in the setting).

    1. Patients whose tumor is not right sided and RAS wild type must also have received an anti-epidermal growth factor receptor (EGFR) therapy.
    2. Patients with tumors harboring mutations or other alterations for which there are available targeted therapies (e.g. BRAF V600E, -positive, MSI-H/dMMR, etc.) must have also received the relevant approved targeted therapies.
    3. If patient received peri-operative treatment (neoadjuvant and/or adjuvant), please consult the Sponsor Medical Monitor for review of prior treatment lines.
  5. At least one lesion measurable as defined by v1.1
  6. (ECOG) Performance Status 0-1
  7. Predicted of at least 12 weeks
  8. Adequate hepatic and renal function within 14 days of C1D1 as described below:

    1. Total ≤ 1.5 X (ULN)
    2. (AST)/ alanine aminotransferase (ALT) ≤ 3.0 X ULN (≤ 5x ULN in case of hepatic metastasis)
    3. Estimated ≥ 30 mL/min based on Cockcroft-Gault estimated creatinine clearance
    4. Urine protein ≤ 1+ by spot urinalysis (or, if > 1+ then 24 hr urine protein \<1.0 g/24 hr)
  9. Female patients who are women of (WCBP) must have a negative pregnancy test (serum-human chorionic gonadotropin [hCG] or urine-hCG) at Screening within 14 days of C1D1
  10. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years or commit to use 2 acceptable forms of (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment
  11. Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Form (ICF) before any protocol-directed screening procedures are performed

Exclusion criteria

Exclusion Criteria:

  1. From the time point of signed ,

    1. Less than 4 weeks have elapsed since patients had a surgery or major procedure
    2. Less than 2 weeks have elapsed from the last treatment date since patients had any radiation therapy
  2. Prior to planned C1D1,

    1. Less than 4 weeks have elapsed since patients had chemotherapy or targeted therapy for colorectal cancer
    2. Less than 4 weeks have elapsed since patients had anticancer immunotherapy or drug treatment
  3. A history of the following cardiovascular diseases in past 5 years may be exclusionary, as determined by the Sponsor Medical Monitor:

    1. Congestive heart failure that corresponds to Class II or a higher class under (NYHA) classification or less than 50% of (LVEF)
    2. Uncontrolled hypertension (systolic blood pressure [SBP]/diastolic blood pressure [DBP] > 140/90 mmHg) (e.g., patient with SBP/DBP > 140/90 mmHg despite the best care including anti-hypertensive medications)
    3. Patients with a history of hypertensive crisis or pre-existing hypertensive encephalopathy
    4. Pulmonary hypertension
    5. Myocardial infarction
    6. Uncontrolled arrhythmia
    7. Unstable angina
    8. Patients with any significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to the initial treatment of the investigational product
  4. Symptomatic or uncontrolled central nervous system (CNS) (However, patients with asymptomatic can participate provided that systemic treatment was discontinued at least 4 weeks prior to screening and that the patient is radiologically and neurologically stable or improving)
  5. A history of the following hemorrhage-related or gastroenterological disease:

    1. Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor invasion into great arteries
    2. History of and active (within 6 months) gastroenterological disease, such as peptic ulcer, gastrointestinal (GI) bleeding, GI or non-GI fistula, perforation, abdominal abscess, clinical symptoms and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease.
  6. Patients who received antiplatelet drugs (aspirin, clopidogrel, etc.) or anticoagulant drugs (warfarin, heparin, direct thrombin inhibitors, etc.) within 2 weeks prior to C1D1, or are expected to need those drugs during the clinical study.
  7. Patients requiring continuous treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids (the following cases are permitted):

    1. NSAIDs: Up to 3 consecutive days' use is permitted
    2. Corticosteroids: Topical use of corticosteroid, such as topical intra-articular injection, intranasal administration, eye drops, inhaler, etc., or temporary systemic corticosteroid use for treatment and prevention of patient's contrast media allergy, or adverse event, is permitted
  8. Severe infection requiring systemic antibiotics, antivirus drugs, etc., or other uncontrolled acute active infectious diseases
  9. Patients with evidence of active virus (HBV) or virus (HCV) infection. Inactive hepatitis B carriers who tested HBsAg positive may enroll provided that the patient's liver function values are normal. Also, patients with chronic HBV infection which has been controlled by the site's treatment guideline may enroll. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll
  10. Patients with other severe diseases or uncontrolled illnesses that warrant the exclusion from the study (permitted only if medically controlled) including but not limited to:

    1. Pre-existing hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days prior to screening
    2. Major, unhealed injury, active ulcer or untreated fracture
    3. History of cerebrovascular incident (ischemic or hemorrhagic stroke), or subarachnoid hemorrhage within 6 months prior to screening
    4. Moderate to severe ascites and/or pleural effusion
  11. Clinically significant abnormal electrocardiography () findings or history determined as clinically significant by the Investigator
  12. (Fridericia's formula) (QTcF) interval > 450 msec at the time of screening
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    CTX-009 Treatment

    Drug: CTX-009

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Secondary outcomes

  1. Disease Control Rate

    Percentage of all treated patients whose best overall response was complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

  2. Duration of Response

    Time from the CT or MRI that first confirmed complete (CR) or partial response PR) to the CT or MRI that first confirmed progression of disease progression (PD). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; PD = 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From first date of complete or partial response to first date of disease progression or death (up to 15.4 weeks)

  3. Progression-free Survival

    Time from first dose of CTX-009 to progression of disease or death. Progression of diseases is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From first dose of CTX-009 to disease progression or death (up to 5.8 months)

  4. Overall Survival

    Time from first dose of CTX-009 to death

    Time frame: From first dose of CTX-009 to death (up to 17.8 months)

  5. Incidence of Treatment-emergent Adverse Events (TEAEs) and Changes in Clinical Abnormalities

    TEAE is defined by occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-009 through 30 days after the last dose of CTX-009. Change in clinical abnormalities is defined as an increase in abnormality grade in a laboratory result, vital sign, or ECG parameter from predose result to worst postdose result (graded according to the Common Terminology Criteria for Adverse Events v5.0 for all analytes except for brain natriuretic peptide and troponin subtypes, which are interpreted in reference to the laboratory reference range for each), a post-baseline potentially clinically significant vital sign abnormality, or a post-baseline potentially clinically significant ECG abnormality.

    Time frame: From the first CTX-009 dose to 30 days after the last CTX-009 dose (average 20 weeks) for TEAEs, from the first CTX-009 dose to 60 days after the last CTX-009 dose (average 25 weeks) for lab tests, vital signs, and ECGs.

07

Results

Posted Jul 28, 2026

Participant flow

The protocol required enrolment of approximately 40 (minimum of 37) response evaluable participants. A total of 49 participants were enrolled in Stage 1, yielding 40 response evaluable participants. The study results did not meet the protocol-defined criterion for progression to Stage 2, and thus enrollment ended after Stage 1.

Participant flow — Overall Study
MilestoneCTX-009 10 mg/kg
Started49
Completed0
Not completed49
Withdrew: Death34
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject7
Withdrew: Study termination by sponsor7

Outcome measures

PrimaryOverall Response Rate

Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.

Time frame:
From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsCTX-009 10 mg/kg
Overall Response Rate2
SecondaryDisease Control Rate

Percentage of all treated patients whose best overall response was complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Reported as:
Count of participants · Participants
Disease Control Rate
ParticipantsCTX-009 10 mg/kg
Disease Control Rate28
SecondaryDuration of Response

Time from the CT or MRI that first confirmed complete (CR) or partial response PR) to the CT or MRI that first confirmed progression of disease progression (PD). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; PD = 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From first date of complete or partial response to first date of disease progression or death (up to 15.4 weeks)
Reported as:
Median · weeks
Duration of Response
weeksCTX-009 10 mg/kg
Duration of Response14.4 (13.3 to 15.4)
SecondaryProgression-free Survival

Time from first dose of CTX-009 to progression of disease or death. Progression of diseases is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
From first dose of CTX-009 to disease progression or death (up to 5.8 months)
Reported as:
Median · months
Progression-free Survival
monthsCTX-009 10 mg/kg
Progression-free Survival3.9 (1.8 to 5.8)
SecondaryOverall Survival

Time from first dose of CTX-009 to death

Time frame:
From first dose of CTX-009 to death (up to 17.8 months)
Reported as:
Median · Months
Overall Survival
MonthsCTX-009 10 mg/kg
Overall Survival10.2 (5.3 to 17.8)
SecondaryIncidence of Treatment-emergent Adverse Events (TEAEs) and Changes in Clinical Abnormalities

TEAE is defined by occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-009 through 30 days after the last dose of CTX-009. Change in clinical abnormalities is defined as an increase in abnormality grade in a laboratory result, vital sign, or ECG parameter from predose result to worst postdose result (graded according to the Common Terminology Criteria for Adverse Events v5.0 for all analytes except for brain natriuretic peptide and troponin subtypes, which are interpreted in reference to the laboratory reference range for each), a post-baseline potentially clinically significant vital sign abnormality, or a post-baseline potentially clinically significant ECG abnormality.

Time frame:
From the first CTX-009 dose to 30 days after the last CTX-009 dose (average 20 weeks) for TEAEs, from the first CTX-009 dose to 60 days after the last CTX-009 dose (average 25 weeks) for lab tests, vital signs, and ECGs.
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events (TEAEs) and Changes in Clinical Abnormalities
ParticipantsCTX-009 10 mg/kg
Treatment-emergent adverse event48
Alanine aminotransferase increased: Grade 0 or 1 to Grade 32
Hypoalbuminemia: Grade 0 or 1 to Grade 27
Alkaline phosphatase increased: Grade 0 or 1 to Grade 25
Aspartate aminotransferase increased: Grade 0 or 1 to Grade 22
Blood bilirubin increased: Grade 0 or 1 to Grade 24
Blood bilirubin increased: Grade 0 or 1 to Grade 33
Hypocalcemia: Grade 0 or 1 to Grade 24
Creatinine increased: Grade 0 or 1 to Grade 210
Creatinine increased: Grade 0 or 1 to Grade 31
Hyperglycemia: Grade 0 or 1 to Grade 213
Hyperglycemia: Grade 0 or 1 to Grade 31
Hyperglycemia: Grade 2 to Grade 31
Lipase increased: Grade 0 or 1 to Grade 22
Lipase increased: Grade 0 or 1 to Grade 33
Hyperkalemia: Grade 0 or 1 to Grade 22
Hyperkalemia: Grade 0 or 1 to Grade 31
Hypokalemia: Grade 0 or 1 to Grade 32
Hyponatremia: Grade 0 or 1 to Grade 22
Hyponatremia: Grade 0 or 1 to Grade 31
Anemia: Grade 0 or 1 to Grade 27
Anemia: Grade 2 to Grade 31
White blood cell count decreased: Grade 0 or 1 to Grade 24
Lymphocyte count decreased: Grade 0 or 1 to Grade 25
Lymphocyte count decreased: Grade 0 or 1 to Grade 32
Lymphocyte count decreased: Grade 2 to Grade 32
Neutrophil count decreased: Grade 0 or 1 to Grade 21
Neutrophil count decreased: Grade 0 or 1 to Grade 31
Neutrophil count decreased: Grade 0 or 1 to Grade 41
Platelet count decreased: Grade 0 or 1 to Grade 24
Activated partial thromboplastin time prolonged: Grade 0 or 1 to Grade 24
International normalized ratio increased: Grade 0 or 1 to Grade 22
Proteinuria: Grade 0 or 1 to Grade 220
Proteinuria: Grade 0 or 1 to Grade 31
Proteinuria: Grade 2 to Grade 32
Brain natriuretic peptide: Low or normal to high16
Troponin subtypes: Low or normal to high7
Systolic blood pressure >= 150 mmHg35
Systolic blood pressure =< 90 mmHg1
Diastolic blood pressure >= 100 mmHg18
Body temperature >= 38 C1
Heart rate >= 100 bpm28
ECG QTcF interval > 450 msec1
ECG QTcF interval =< 450 msec49
ECG PR interval >= 200 msec2
ECG QRS duration >= 120 msec3
ECG heart rate >= 100 bpm10

Adverse events

Collected over Adverse events were collected from the signing of the informed consent form to 30 days after the last dose of CTX-009 (average 20 weeks). All-cause mortality data were collected was from the first dose of CTX-009 to death (up to 17.8 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CTX-009 10 mg/kg34/49 (69.4%)14/49 (28.6%)47/49 (95.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCTX-009 10 mg/kg
AscitesGastrointestinal disorders2/49
ColitisGastrointestinal disorders2/49
HyponatraemiaMetabolism and nutrition disorders2/49
Abdominal distensionGastrointestinal disorders1/49
Abdominal pain upperGastrointestinal disorders1/49
Enterovesical fistulaGastrointestinal disorders1/49
Oesophageal ulcer haemorrhageGastrointestinal disorders1/49
Small intestinal obstructionGastrointestinal disorders1/49
Varices oesophagealGastrointestinal disorders1/49
AppendicitisInfections and infestations1/49
Most frequent other events
Showing 10 of 29
Most frequent other events
EventCTX-009 10 mg/kg
HypertensionVascular disorders22/49
ProteinuriaRenal and urinary disorders18/49
NauseaGastrointestinal disorders14/49
FatigueGeneral disorders13/49
Weight decreasedInvestigations11/49
HeadacheNervous system disorders10/49
Cardiac failureCardiac disorders9/49
DiarrhoeaGastrointestinal disorders8/49
Decreased appetiteMetabolism and nutrition disorders8/49
Oedema peripheralGeneral disorders7/49

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CTX-009 10 mg/kg
<=18 years0
Between 18 and 65 years32
>=65 years17
Age, Continuous
Age, Continuous(years)CTX-009 10 mg/kg
Mean58.6 ± 11.54
Sex: Female, Male
Sex: Female, Male(Participants)CTX-009 10 mg/kg
Female17
Male32
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CTX-009 10 mg/kg
Hispanic or Latino3
Not Hispanic or Latino43
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CTX-009 10 mg/kg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White43
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)CTX-009 10 mg/kg
United States49
08

Study locations

7 sites
  • Genesis Cancer and Blood Institute
    Hot Springs, Arkansas 71913, United States
  • Florida Cancer Specialists & Research Institute - South
    Fort Myers, Florida 33916, United States
  • Florida Cancer Specialists & Research Institute - North
    St. Petersburg, Florida 33705, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Zangmeister Cancer Center
    Columbus, Ohio 43219, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2025, 29 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 29 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 24, 2022
StartActual
Dec 8, 2022
Primary completionActual
May 15, 2025
CompletionActual
May 15, 2025
Results first posted
Jul 28, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Posted results revised

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05513742
Lead sponsor
Compass Therapeutics
Responsible party
Sponsor
First posted
Aug 24, 2022
Start date
Dec 8, 2022
Primary completion
May 15, 2025
Completion
May 15, 2025
Results posted
Jul 28, 2026
Last update
Sep 25, 2026

Study contacts

Minori Rosales, MD, PhD
study director · Compass Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovecimig

Start the discussion